- CME/CE Activities
- Type 2 Diabetes: Discussing Applications to Clinical Practice
This CME/CE activity is provided by PRIME Education, Inc. (PRIME®) and is accredited for a multi-disciplinary audience of health care practitioners. This activity is supported by contract number HHSA290201200021I from the Agency for Healthcare Research and Quality. User data collected through this activity will reside on PRIME's educational portal for use by AHRQ.
Comparative Effectiveness Research on Premixed Insulin Analogues for Type 2 Diabetes: Discussing Applications to Clinical Practice
- Program Overview
- Faculty Biographies
- Accreditation Statements
- Post-Test & Evaluation
Credit for this CME/CE activity has expired.
You can still access the program, but will not receive a certificate.
Many people with type 2 diabetes are not able to achieve blood glucose targets with oral noninsulin medications alone. For these patients, exogenous insulin therapy is essential for preventing diabetes-related complications. Diabetes management has been significantly advanced by the development of insulin analogues, which are synthetic preparations that resolve some of the pharmacokinetic limitations and adherence barriers of conventional human insulin therapies. Novel premixed insulin analogues, which require only 1 or 2 daily injections, are designed to control both fasting and prandial glucose excursions.
Until recently, no comprehensive study had been conducted on the benefits and harms of premixed insulin analogues versus other insulin therapies and noninsulin oral antidiabetic agents. In 2008, a comparative effectiveness review on this topic was published with support from the Agency for Healthcare Research and Quality (AHRQ). This educational activity – featuring the first author of the AHRQ systematic review and a leading nurse practitioner who specializes in diabetes care – presents an engaging case-based discussion about the review findings and their potential applications in clinical practice.
At the conclusion of this activity, the participant should be able to:
- Summarize the major findings from AHRQ's systematic review on the comparative effectiveness of premixed insulin analogues for adults with type 2 diabetes
- Explain the tradeoffs in benefits versus harms for premixed insulin analogues, other insulin preparations, and noninsulin antidiabetic drugs
- Demonstrate effective strategies for communicating comparative effectiveness research findings to patients
- Apply AHRQ's systematic review findings to educating patients about options for insulin therapies and to making patient-centered treatment and management decisions
This CME activity is designed to meet the educational needs of physicians, nurse practitioners, pharmacists, nurses, dieticians, medical assistants, health education specialists.
Method of Participation
To receive a certificate for this activity, you should:
- Complete the learner assessment pretest
- View the entire activity online (Hardware/Software Requirements: Broadband & Flash Player or HTML5 browser)
- Complete an online evaluation & post-test
- Print your certificate online
The estimated time to complete this activity, including review of the materials, is 1.0 hour.
Term of Approval
March 31, 2011 through March 30, 2013. Original release date: March 31, 2011.
Acknowledgement of Support
There is no fee for this CME/CE activity. This activity is sponsored by PRIME Education, Inc (PRIME®) and funded under contract HHSA290201200021I from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS).
Faculty Biographies and Disclosures
Assistant Professor of Medicine
Division of General Internal Medicine/Hospitalist Program
Johns Hopkins School of Medicine
Lead investigator of the AHRQ's diabetes systematic review in comparative effectiveness research of premixed insulin analogues
Dixie L Harms, DNP, ARNP, FNP-C, BC-ADM, FAANP
Family Nurse Practitioner
Mercy Family Medicine of Urbandale
Adjunct Clinical Faculty
University of Iowa College of Nursing
Iowa City, IA
Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
National Clinical Nursing Director
Department of Neurology
Multiple Sclerosis Center of Excellence, East
Veterans Affairs Medical Center
Trinity Nursing Program School of Professional Studies
Trinity Washington University
Clinical Preceptor and Instructor
Advanced Practice Programs
The Catholic University of America School of Nursing
Michele B Kaufman, PharmD, CGP, RPh
President, PRN Communications Inc.
Editor, Pharmacovigilance Forum, P&T Journal
Touro College of Pharmacy
New York, NY
Wanda F Carter, MPH, CHES
Adjunct Professor, Kaplan University Master of Public Health Program
Adjunct Professor, Axia College (U of Phoenix) Health Care Administration Program
Adjunct Professor, LA College International Health Care Administration Program
Adjunct Professor, Ashford University Health Care Administration Program
PHPS Alumnus, CDC Scientific Education and Professional Development Program Office
Sherman Podolsky, MD
Department of Emergency Medicine
Albert Einstein Medical Center
Donna M Chiefari, BSc (Pharm), PharmD, RPh, FASHP
Adjunct Faculty & Preceptor
Albany College of Pharmacy
Heather Katz, CDE, RD, LD/N
Operations & Clinical Nutrition Manager
Aventura Hospital & Medical Center
Joyce M Knestrick, PhD, CRNP, FAANP
Coordinator of Graduate Education
Frontier School of Midwifery and Family Nursing
Certified Family Nurse Practitioner
The Primary Care Center
Mt Morris, PA
Kathleen A Jarvis, MS, RN, CCM
Fort Lauderdale, FL
This program is no longer accredited.
|Faculty Name ||Advisory Board||Consultant||Grants / Research||Salary / Contractual||Supported Promotional Education||Stock / Shareholder||Other Financial Support|
|Dixie L Harms, DNP, ARNP, FNP-C, BC-ADM, FAANP
|None||None||AANP Foundation Grant||None||Merck||None||None|
|Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
|Michele B Kaufman, PharmD, CGP, RPh
|Wanda F Carter, MPH, CHES
|Sherman Podolsky, MD
|Donna M Chiefari, BSc (Pharm), PharmD, RPh, FASHP
|Heather Katz, CDE, RD, LD/N
|Joyce M Knestrick, PhD, CRNP, FAANP
|Kathleen A Jarvis, MS, RN, CCM
|Chris R Prostko, PhD|
Scientific Program Director
|Lynn Goldenberg, RN, BSN|
Director of Accreditation & Compliance
PRIME Education Inc (PRIME®) endorses the standards of the ACCME, as well as those of the AANP, ANCC and ACPE, that require everyone in a position to control the content of a CME/CE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CE activity. CME/CE activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when individuals in a position to control the content of CME/CE have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
PRIME® willidentify, review and resolve all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff are provided with this activity.
Presentations that provide information in whole or in part related to non FDA approved uses of drugs and/or devices will disclose the unlabeled indications or the investigational nature of their proposed uses to the audience. Participants should refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Participants should verify all information and data before treating patients or employing any therapies prescribed in this educational activity. The opinions expressed in the educational activity are those of the presenting faculty and do not necessarily represent the views of PRIME®, the ACCME, AANP, ACPE, ANCC and other relevant accreditation bodies.
Content validation methods are consistently utilized by PRIME® to ensure that all program content is evidence-based, fair-balanced, and developed with scientific rigor and integrity. All clinical recommendations are based on evidence accepted within the medical profession. All scientific research referred to, reported or used to support a clinical recommendation conforms to accepted standards of experimental design, data collection and analysis. In addition to review of content by course directors and expert faculty, content is also validated through independent peer reviewers selected for their expertise in the content area, as well as their experience in the intended audience. All peer reviewers, planners, course directors, faculty and relevant staff utilized by PRIME® complete disclosures which are related to their role in the educational activity.
PRIME®is committed to providing access to our CME programs for individuals with disabilities as identified in Section 508 of the Rehabilitation Act for all web-based programs. This website is 508 compliant.
To play the video below, your device must support HTML5 video (ex: iPad, Android, Chrome) or have Adobe Flash Player installed. Closed captioning is available by clicking the "CC" button in the top right of the video player. Click Here to access a transcript of this activity.
Post-Test & Evaluation
Credit for this program has expired.
If you already completed this program and need to reprint your certificate(s), login here.
Clinician & Consumer Summaries on Premixed Insulin Analogues
Download these free summaries for your reference and/or patient handouts. You may also order bulk copies free of charge from the AHRQ Publication Clearinghouse below.